- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01330680
Genetic Determinants of Cardiovascular Response to Coffee Drinking
Cardiovascular and neuropsychologic effects of coffee are still debated. The precise mechanism underlying the actions of caffeine on the cardiovascular and neuropsychologic systems is incompletely understood and a considerable variability in the response to coffee drinking was observed, in part ascribable to a genetic trait.
The aim of the study is to evaluate acute cardiovascular and neuropsychologic effects of coffee and explore whether such effects are influenced by the genetic asset of caffeine metabolism (by a polymorphisms of cytochrome P450 1A2), adenosine metabolism (by polymorphisms of adenosine receptor and adenosine monophosphate deaminase) or catecholamine receptors (by polymorphisms of adrenergic receptors).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Coffee is among the most widely consumed beverages worldwide. Despite the relationship between coffee consumption and the incidence of cardiovascular disease has been studied extensively, the effects of this drink on the cardiovascular apparatus and its role as a risk factor for coronary heart disease are still debated. Moreover, the effect of coffee on attention, sleep changes, anxiety and panic disorders was studied but a great variability was observed.
Many of the known or suspected cardiovascular and neuropsychologic effects of coffee have been attributed to caffeine. The main mechanism of action of caffeine is to antagonize adenosine receptors; a secondary effect is the inhibition of phosphodiesterases, with the subsequent accumulation of cyclic adenosine monophosphate and a intensification of the effects of catecholamines.
It is also well known that there is a considerable variability in the cardiovascular and neuropsychologic response to coffee drinking, explaining the inconsistency between different effects observed in the various studies. This variability may have a genetic basis.
The aim of the study is to evaluate acute cardiovascular and neuropsychologic effects of coffee and explore whether such effects are influenced by the genetic asset of caffeine metabolism (by a polymorphisms of cytochrome P450 1A2), adenosine metabolism (by polymorphisms of adenosine receptor and adenosine monophosphate deaminase) or catecholamine receptors (by polymorphisms of adrenergic receptors).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Chieti, Italy, 66100
- Institute of Cardiology - Center of Excellence on Aging, G. d'Annunzio University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 40 years
- Males (to avoid variation due to female hormonal cycle)
- No known active ongoing disease (apparent good health)
- Non-smokers (to avoid contributory effects of nicotine or other tobacco alkaloids to caffeine effects or tolerance)
- Average coffee intake (not less than one cup/day and not greater than three cups/day)
Exclusion Criteria:
- Treatment with any drug with known activity on the adrenergic system
- Hypertension
- Therapy with sympathomimetic drugs, theophylline, alpha- or beta-blockers, any antihypertensive therapy
- Body mass index (BMI) > 30 kg/m2 (obesity)
- BMI < 18.5 kg/m2
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Coffee
|
40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
|
Active Comparator: Decaffeinated coffee
|
40 mL dose of decaffeinated coffee
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in platelet aggregation
Time Frame: From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively
|
Light transmission aggregometry (LTA) induced by ADP and apinephrine.
Platelet function analyzer (PFA) by collagen-ADP and collagen-epinephrine cartridges.
|
From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively
|
Change in cognitive tasks measures
Time Frame: From 30 minutes until 2 hours after coffee or decaffeinated alternatively
|
Low intensity task of focused attention and choice reaction times (Categorical Search Task). More demanding response interference tasks (Letter Flanker Task). Classic interference task (Stroop Test). |
From 30 minutes until 2 hours after coffee or decaffeinated alternatively
|
Change in blood pressure
Time Frame: From baseline until 2 hours after coffee or decaffeinated alternatively
|
From baseline until 2 hours after coffee or decaffeinated alternatively
|
|
Change in heart rate
Time Frame: From baseline until 2 hours after coffee or decaffeinated alternatively
|
From baseline until 2 hours after coffee or decaffeinated alternatively
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in plasma caffeine concentration
Time Frame: From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively
|
From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively
|
Change in plasma adrenaline and noradrenaline concentration
Time Frame: From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively
|
From baseline to 30 minutes and 2 hours after coffee or decaffeinated alternatively
|
Collaborators and Investigators
Publications and helpful links
General Publications
- 1) Hartley TR, Lovallo WR, Whitsett TL. Cardiovascular effects of caffeine in men and women. Am J Cardiol 2004;93:1022-6. 2) Lopez-Garcia E, van Dam RM, Willett WC, et al. Coffee consumption and coronary heart disease in men and women: a prospective cohort study. Circulation 2006;113:2045-53. 3) Silletta MG, Marfisi R, Levantesi G, et al. Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)-Prevenzione trial. Circulation 2007;116:2944-51. 4) Yang A, Palmer AA, de Wit H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 2010;211:245-57. 5) Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295:1135-41. 6) Fredholm BB. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 1995;76:93-101. 7) Anderson JL, Habashi J, Carlquist JF, et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000;36:1248-52. 8) Snapir A, Heinonen P, Tuomainen TP, et al. An insertion/deletion polymorphism in the alpha2B-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001;37:1516-22. 9) Bengtsson K, Melander O, Orho-Melander M, et al. Polymorphism in the beta(1)-adrenergic receptor gene and hypertension. Circulation 2001;104:187-90. 10) White HL, Maqbool A, McMahon AD, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur Heart J 2002;23:1087-92. 11) Brodde OE. Beta-1 and beta-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther 2008;117:1-29.
- Renda G, Zimarino M, Antonucci I, Tatasciore A, Ruggieri B, Bucciarelli T, Prontera T, Stuppia L, De Caterina R. Genetic determinants of blood pressure responses to caffeine drinking. Am J Clin Nutr. 2012 Jan;95(1):241-8. doi: 10.3945/ajcn.111.018267. Epub 2011 Dec 14.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- C041003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Caffeine
-
Ain Shams UniversityCompletedCaffeine | Caffeine Withdrawal | Caffeine DependenceEgypt
-
Psychiatric Hospital of the University of BaselSwiss National Science FoundationCompletedSleep | Circadian Rhythm | Caffeine | Caffeine WithdrawalSwitzerland
-
St. Mary's University, TwickenhamNot yet recruiting
-
St Mary's University CollegeNot yet recruiting
-
Wake Forest University Health SciencesThe Hershey CompanyCompleted
-
Technical University of LisbonCompleted
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSleep Disorder | Diarrhea | Anxiety Disorders | Insomnia | Sleep Initiation and Maintenance Disorders | Anxiety | Sleep Disturbance | Gastrointestinal Dysfunction | Heartburn | Caffeine | Caffeine Withdrawal | Caffeine; Sleep Disorder | Caffeine Dependence | Caffeine-Induced Anxiety Disorder | Caffeine-Induced Sleep... and other conditionsUnited States
-
National Taiwan Sport UniversityCompleted
-
Vedic Lifesciences Pvt. Ltd.Completed
-
Carolin ReichertPontificia Universidad Catolica de Chile; Swiss National Science Foundation; University...Completed
Clinical Trials on Coffee
-
University Hospital HeidelbergUnknown
-
University of California, San FranciscoRecruiting
-
Mondelēz International, Inc.St. Luke's-Roosevelt Hospital CenterCompleted
-
University of British ColumbiaUnknownInflammatory Response | Cognitive Function | Leukocytosis | TriglyceridesCanada
-
Eastern Mediterranean UniversityCompletedCardiovascular DiseasesCyprus
-
Cedars-Sinai Medical CenterCompletedPostoperative IleusUnited States
-
University of ChileSociété des Produits Nestlé (SPN)Completed
-
Assistance Publique - Hôpitaux de ParisRecruitingADCY5-related DyskinesiaFrance
-
West German Center of Diabetes and HealthTchibo GmbHCompleted
-
Massachusetts Eye and Ear InfirmaryCompleted